Cargando…

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Therapy options for patients with metastatic melanoma (MM) have considerably improved over the past decade. However, many patients still need effective therapy after unsuccessful immunotherapy, especially patients with BRAF-negative tumors who lack the option of targeted treatment second line. There...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohtamäki, Laura, Arjama, Mariliina, Mäkelä, Siru, Ianevski, Philipp, Välimäki, Katja, Juteau, Susanna, Ilmonen, Suvi, Ungureanu, Daniela, Kallioniemi, Olli, Murumägi, Astrid, Hernberg, Micaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633005/ https://www.ncbi.nlm.nih.gov/pubmed/34837846 http://dx.doi.org/10.1016/j.tranon.2021.101290

Ejemplares similares

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
por: Murumägi, Astrid, et al.
Publicado: (2021)

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
por: Murumägi, Astrid, et al.
Publicado: (2022)

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
por: Kasanen, Henna, et al.
Publicado: (2020)

Pelvic sentinel lymph nodes have minimal impact on survival in melanoma patients
por: Vuoristo, Mikko, et al.
Publicado: (2021)

Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
por: Jacome Sanz, Dafne, et al.
Publicado: (2021)

Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness
por: Karvonen, Hanna, et al.
Publicado: (2020)

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention
por: Raivola, Juuli, et al.
Publicado: (2022)

BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas
por: Manninen, Atte A., et al.
Publicado: (2019)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors
por: Kolberg, Matthias, et al.
Publicado: (2017)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
por: Bruun, Jarle, et al.
Publicado: (2021)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms
por: Kangaspeska, Sara, et al.
Publicado: (2012)

Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
por: Vachtenheim, Jiri, et al.
Publicado: (2021)

Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells
por: Ketola, Kirsi, et al.
Publicado: (2012)

A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses
por: Härmä, Ville, et al.
Publicado: (2010)

Identification of NRAS Diagnostic Biomarkers and Drug Targets for Endometrial Cancer—An Integrated in Silico Approach
por: Alessandro, Larsen, et al.
Publicado: (2022)

Membrane-Type-3 Matrix Metalloproteinase (MT3-MMP) Functions as a Matrix Composition-Dependent Effector of Melanoma Cell Invasion
por: Tatti, Olga, et al.
Publicado: (2011)

High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells
por: Hongisto, Vesa, et al.
Publicado: (2013)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma
por: Mäkelä, Rami, et al.
Publicado: (2020)

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
por: Jernström, Sandra, et al.
Publicado: (2017)

Increased incidence of melanoma in children and adolescents in Finland in 1990–2014: nationwide re-evaluation of histopathological characteristics
por: Rousi, Emma K., et al.
Publicado: (2022)

SynergyFinder 2.0: visual analytics of multi-drug combination synergies
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients
por: Åkerlund, Emma, et al.
Publicado: (2023)

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis
por: Khan, Suleiman A., et al.
Publicado: (2014)

High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer
por: Vainio, Paula, et al.
Publicado: (2012)

Ex Vivo Drug Screening Informed Targeted Therapy for Metastatic Parotid Squamous Cell Carcinoma
por: Nykänen, Noora, et al.
Publicado: (2021)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity
por: Piki, Emilia, et al.
Publicado: (2023)

Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma
por: Lohse, Ines, et al.
Publicado: (2018)

DrugEx: Deep Learning Models and Tools for Exploration of Drug-Like Chemical Space
por: Šícho, Martin, et al.
Publicado: (2023)

DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs)
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

Novel Synergistic Anti-Enteroviral Drug Combinations
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

Identification of fusion genes in breast cancer by paired-end RNA-sequencing
por: Edgren, Henrik, et al.
Publicado: (2011)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2017)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion
por: Lehtinen, Laura, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t4anmhtr9t7kq4o9nnlfc5hosc